To review and summarize experimental data examining the effects of different fractions of meconium, and to test the effect of albumin on meconium aspiration both as prophylactic and rescue treatment. Newborn piglets 2 to 5 days of age were made hypoxic and then instilled meconium or fractions of meconium intratracheally. Meconium-added albumin and albumin instilled after meconium were also tested. Lung function and inflammatory cytokines were measured. Both the lipid-and water-soluble fractions induce inflammation in the lungs with elevation of inflammatory cytokines. When meconium was mixed with albumin, the inflammatory effects of meconium were significantly ameliorated. Rescue therapy with intratracheal albumin 5 min after the meconium aspiration syndrome was induced also improved lung function. These results indicate that at least part of the symptoms seen in the meconium aspiration syndrome could be prevented by blocking the active substances of meconium such as bile acids and free fatty acids.
Introduction
Aspiration of meconium in the airways of the newborn infant leads to plugging and subsequently to inflammatory changes, surfactant inhibition, respiratory failure and pulmonary hypertension. There have been three approaches to moderate these effects: (1) dilute meconium (amnioinfusion, lavage), (2) improve/'strengthen' surfactant by adding for instance polymers and (3) inhibit harmful effects of meconium per se.
Meconium is a complex mixture containing 75 to 80% water. The other chemical components can be divided into lipid-and water-soluble material. The lipid includes free fatty acids (FFA), triglycerides and cholesterol. The FFA include mainly palmitic, stearic and oleic acids. The water-soluble components include bile acids, bilirubin, dietary fibers and inorganic molecules. The main bile acids of meconium are cholic, hydroxycholic and chenodeoxycholic acids. [1] [2] [3] These different subfractions of meconium are leading to reduced activity of surfactant and inflammation therefore promoting atelectasis and impaired gas exchange. Both hydrophilic and hydrophobic components of meconium reduce surfactant function. Furthermore, the lipid fraction has a stronger inhibitory effect on surfactant function than the water-soluble subfraction. [4] [5] [6] [7] It is well known that bile salts may cause inflammation 8, 9 and that FFA, such as oleic acid, induce severe lung failure when administered intravenously. 10 We have tested the effects of different meconium subfractions on pulmonary function in an animal model of newborn piglets. Because albumin is able to bind FFA, we also examined whether albumin added to meconium alleviates the clinical symptoms of meconium aspiration. In case such an inhibitory effect was found, perhaps this also could be used as rescue therapy. We therefore developed a rescue model instilling albumin intratracheally following meconium aspiration. In this article we summarize and review some of our previous results.
Methods
We used newborn piglets undergoing hypoxia and meconium aspiration followed by resuscitation. 11 Human meconium was collected from healthy term newborns and diluted in distilled water, and rotavaporated dry. It was sterilized by g-irradiation and diluted with sterile water to 110 mg dry weight per ml. Hypoxia with FiO 2 of 0.08 was induced in newborn piglets 2 to 5 days of age until they were close to collapse. The piglets were then hand-ventilated for 30 s and put back on ventilator with rate increased from 30 to 60 per min, and peak inspiratory pressure increased to 5 Cm H 2 O. Tidal volume was kept constant at 10 to 15 ml kg À1 and paCO 2 4.5 to 6 kPa (34 to 45 mm Hg). In the first study 3 ml kg À1 body weight of meconium was instilled intratracheally giving an oxygenation index (OI) of 6 to 7 indicating a mild meconium aspiration syndrome (MAS). In this study meconium was also mixed with albumin (30% albumin in stoichiometric relation to FFA estimated to be 1.4 ml kg À1 ) before intratracheal in administration of the mixture. 12, 13 In the second study 3 ml kg À1 body weight of either meconium, lipid-or water-soluble meconium fractions was instilled intratracheally in separate groups. 14 In the third study a moderate and severe model was developed. A moderate MAS was developed by instilling meconium of 4 ml kg À1 body weight, giving an OI of approximately 12. A severe MAS was induced by instilling 5 ml meconium mixture per kg leading to a typical OI of 25. Five min after meconium had been instilled, 3 ml of 30% albumin was instilled intratracheally. 15 The animals in all studies were resuscitated for 8 h with room air or supplemental O 2 to achieve a SaO 2 of 85%.
Results

Effect of albumin
Animals receiving albumin mixed with meconium compared with meconium alone had a significantly reduced OI as well as ventilation index. OI was approximately 50% in animals given meconium mixed with albumin compared with those given meconium. The need for oxygen and mean airway pressure on the ventilator was also significantly reduced and compliance increased in animals given the combination of meconium and albumin. 12 The inflammatory cytokine interleukin (IL)-8 in tracheal aspirate, 8 h after reoxygenation was started, was in mean fivefold higher (P<0.05) in animals given meconium alone (93 pg ml À1 ) as compared to those given meconium mixed with albumin (18 pg ml À1 ) before intratracheal instillation. 13 
Effect of meconium fractions
Both the lipid-and water-soluble fractions of meconium induced inflammatory changes, however, more in the lipid extract than the water extract group. At 8 h after instillation of meconium, IL-8 in tracheal aspirate was threefold higher in the lipid extract group than in the animals given the water-soluble fractions of meconium. Intact meconium had more severe effects on the lungs than the lipid-and water-soluble fractions of meconium separately. 14 
Effect of rescue therapy with albumin
Rescue therapy with a low-dose intratracheal albumin (stoichiometric binding of FFA) did not affect OI or IL-8 in tracheal aspirate when measured at 8 h. However, a significantly attenuated decrease in lung compliance was found. 15 
Discussion
In these studies we found that albumin inhibits clinical effects of meconium and that the lipid fraction is more harmful than the water fraction. Rescue therapy with albumin increases compliance but does not seem to have significant clinical effects in the doses and administration tested out. Both the lipid-and water-soluble fractions of meconium induce pulmonary inflammation and injury, however, less than meconium alone. The lipid fraction was responsible for most of the cytokine activation assessed by IL-8 in tracheal aspirate. However, the water-soluble fraction also had some inflammatory properties.
We chose albumin as a protein with high capacity to bind FFA in spite of the fact it is known that albumin also inhibits surfactant function. However, in our animal model, and probably in patients with MAS as well, surfactant function is already abolished.
Albumin added to meconium before intratracheal instillation, almost completely blocked the negative effects of meconium. Albumin seems to prevent development of MAS when added to meconium. However, when albumin is given as rescue therapy the effect is less clear. In another of our studies rescue therapy by lavaging the lungs with excess albumin gave worse outcome than meconium alone (submitted). Rescue therapy with albumin in low doses and low volume therefore had a small but significant and positive effect on compliance, however, larger doses and volumes seem to have a detrimental effect on pulmonary function.
The optimal albumin dose, timing and mode of administration therefore are unknown. Other inhibitors of both the lipid-and water-soluble fractions of meconium should be searched for and tested aiming at developing an efficient rescue therapy. Several such inhibitors as polymers and anti-inflammatory agents 16, 17 have been described already. Furthermore, meconium-induced apoptosis may be inhibited by angiotensin-converting enzyme inhibitors, which may reduce injury. 18, 19 Meconium is a potent complement activator and complement inhibition may represent a future therapeutic principle in MAS. 20 In the future all the principles discussed above may be combined to develop a powerful therapy for MAS. Given the available presented data, there does not appear to be a robust argument for the use of albumin in the human infant with meconium aspiration, let alone suggest that there may be 'an optimum dose', timing and mode of administration.
